Results 311 to 320 of about 21,521,804 (362)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Chromosome X-wide association study in case control studies of pathologically confirmed Alzheimer's disease in a European population. [PDF]

open access: yesTransl Psychiatry
Simmonds E   +9 more
europepmc   +1 more source

Liver and renal biochemical profiles of people with sickle cell disease in Africa: a systematic review and meta-analysis of case-control studies. [PDF]

open access: yesSyst Rev
Awor S   +10 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Case–Control Studies

AJN, American Journal of Nursing, 2022
Editor's note: This is the eighth article in a series on clinical research by nurses. The series is designed to give nurses the knowledge and skills they need to participate in research, step by step. Each column will present the concepts that underpin evidence-based practice—from research design to data interpretation. The articles will be accompanied
Courtney, Keeler, Alexa Colgrove, Curtis
openaire   +3 more sources

Home - About - Disclaimer - Privacy